Related Experiment Videos
Treatment versus no treatment in chronic open angle glaucoma
C Holmin1, W Thorburn, C E Krakau
1University Eye Clinic, Lund, Sweden.
Acta Ophthalmologica
|April 1, 1988
Summary
This study found no significant difference in visual field progression between treated and untreated glaucoma patients. However, the research highlights challenges in conducting randomized glaucoma trials with real-world patient compliance.
Area of Science:
- Ophthalmology
- Clinical Trials
- Glaucoma Research
Background:
- Chronic open-angle glaucoma is a leading cause of irreversible blindness.
- Visual field defects are a key indicator of glaucoma progression.
- Effective management aims to reduce intraocular pressure to prevent further optic nerve damage.
Purpose of the Study:
- To evaluate the efficacy of pressure-reducing medical therapy in slowing visual field progression in chronic open-angle glaucoma.
- To assess the feasibility of conducting a randomized controlled trial in glaucoma patients.
Main Methods:
- A controlled randomized study involving 15 patients with chronic open-angle glaucoma and visual field defects.
- Patients were divided into treated (medical therapy) and untreated control groups.
- Computerized visual fields (COMPETER) were recorded, and linear regression coefficients were calculated over a follow-up period exceeding one year.
Main Results:
- No significant difference in the rate of visual field progression was observed between the treated and untreated groups.
- The treated group achieved an average intraocular pressure reduction of 4 mmHg.
- The study noted limitations including small sample size and uncontrolled patient compliance.
Conclusions:
- The study suggests that, within its limitations, pressure-reducing medical therapy did not demonstrate a statistically significant favorable effect on visual field progression in this cohort.
- Conducting randomized controlled trials for glaucoma, adhering to strict conventions, presents significant practical challenges, particularly regarding patient compliance and sample size.